Using a murine model of chronic myeloid leukemia (CML) stem cells transplantation, Eklund’s group reported that administration of the SLV peptide (to inhibit PTPN13), in addition to the standard treatment with the BCR/ABL inhibitor imatinib, delays tumor development, suggesting an inhibition of leukemia stem cell persistence [61]. This evidence concerns the gene PTPN13 and chronic myelogenous leukemia, BCR-ABL1 positive.